- Home
- AMBQ vs ENGN Comparison
AMBQ vs ENGN Comparison
Compare AMBQ & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AMBQ | ENGN |
|---|---|---|
| Founded | 2010 | 1999 |
| Country | United States | Canada |
| Employees | N/A | 82 |
| Industry | Semiconductors | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 634.4M | 647.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | AMBQ | ENGN |
|---|---|---|
| Price | $28.65 | $8.69 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $41.75 | $22.17 |
| AVG Volume (30 Days) | ★ 266.9K | 232.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $19.49 | N/A |
| Revenue Next Year | $29.11 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $22.12 | $2.66 |
| 52 Week High | $43.06 | $12.25 |
Technical Indicators
Market Signals| Indicator | AMBQ | ENGN |
|---|---|---|
| Relative Strength Index (RSI) | 42.82 | 37.83 |
| Support Level | $28.11 | $7.83 |
| Resistance Level | $30.15 | $9.40 |
| Average True Range (ATR) | 1.64 | 0.57 |
| MACD | -0.15 | -0.17 |
| Stochastic Oscillator | 10.58 | 9.58 |
Price Performance
Historical ComparisonAbout AMBQ Ambiq Micro Inc.
Ambiq Micro Inc is a fabless semiconductor company that has developed technology based on a patented Sub-threshold Power Optimized Technology (SPOT) platform that significantly reduces the amount of power consumed by integrated circuits. It is a pioneer and provider of ultra-low power semiconductor solutions designed to address the significant power consumption challenges of general purpose and AI compute - especially at the edge.
About ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company mainstreaming genetic medicine through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs, beginning with non-muscle invasive bladder cancer (NMIBC). The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.